Lonza’s $1.2B Roche Biologics Plant Deal Shakes Up CDMO Market


Lonza, a leading Swiss contract development and manufacturing organization (CDMO), has announced the acquisition of Roche’s biologics facility in Vacaville, California, for $1.2 billion in cash. The deal, which is expected to close in the second half of 2023, will significantly expand Lonza’s manufacturing capacity and capabilities in the rapidly growing biologics market.

The Vacaville facility is one of the largest and most advanced biologics manufacturing sites in the world, with over 1,000 employees and a total area of approximately 1.6 million square feet. The site has a strong track record of producing a wide range of biologics, including monoclonal antibodies, therapeutic proteins, and other complex molecules.

The acquisition is a strategic move for Lonza, as it will enable the company to meet the increasing demand for biologics manufacturing services from its global customers. The deal also highlights the ongoing consolidation in the CDMO industry, as companies seek to expand their capabilities and geographic reach to better serve their clients in the competitive market.